EUCTR2017-000391-28-ES进行中（未招募）1 期
A PHASE II, DOUBLE-BLIND, CONTROLLED, PARALLEL-ARM TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A SINGLE INFUSION OF ALLOGENIC MESENCHYMAL STEM CELLS IN LUPUS NEPHRITIS (LN) - ALLOGENIC MESENCHYMAL STEM CELLS IN NEPHRITIS LUPUS
INSTITUTO DE ESTUDIOS DE CIENCIAS DE LA SALUD DE CASTILLA Y LEO0 个研究点开始时间: 2017年5月29日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Male or female = 18 yrs with written informed consent.
- •2.SLE diagnosis fulfiilling at least 4 out of the 11 ACR criteria during the course of their illness.
- •3.Diagnosis of LN class (2003 classification by International Society of Nephrology/Renal Pathology Society) by biopsy less than 6 months prior.
- •4.No response or partial response to induction therapy after at least three months with cyclophosphamide (750 mg/m² body surface/mo) or mycophenolat mofetil (2-2.5 gr/day) or mycophenolate sodium (1.040-1.800 mg/day) plus corticoids = 40 mg per day. Complete response criteria is: glomerular filtration rate = 60 ml/min/1,73m², or decline to baseline or ± 15% of baseline in those with glomerular filtration rate < 60 ml/min/1,73m², proteinuria = 0.5 g in 24 h, inactive sediment (= 5 erythrocytes, = 5 lymphocytes or cell casts) and serum albumin > 3gr/d. Partial response means patients with basal proteinuria = 3.5 g in 24 h that declines < 3.5 grams in 24 h; patients with basal proteinuria < 3.5 g in 24 h that declines > 50%; stabilization or improvement of glomerular filtration rate in both situations. SLEDAI-2K score = 6 at selection period.
- •5.Women subjects of childbearing potential must use a highly effective method of contraception to prevent pregnancy. 6. History of vaccinations against S. pneumococcus, H. influenza and seasonal vaccinations, as required.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 36
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Use of corticoids, mycophelolate, cyclophosphamide above doses permitted for induction, according to the Consensus Document of the Group of Systemic Autoimmune Diseases of the Spanish Society of Internal Medicine and the Spanish Society of Nephrology.
- •2.Use of rituximab, belimumab or ocrelizumab, or other B cell-directed biologic therapies within 1 yr before treatment.
- •3.Use of abatacept within 1 yr before treatment.
- •4.Use of any tumor necrosis factor (TNF) inhibitor therapy within 1 yr before selection.
- •5.Use of immunoglobulin treatment within 1 yr before treatment.
- •6.Change in dosage of an angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) within 2 months before treatment.
- •7.Treatment with other investigational agents within the last 3 months or 5 half-lives prior to treatment.
- •8.Exclusion criteria related to medical conditions:
- •a.Any condition that in the investigator´s opinion constitutes an unnecessary risk or a counterindication for participation.
- •b.History of or planned renal or other organ transplant.
- •c.Positive human immunodeficiency virus or hepatitis C Ab and/or PCR, or hepatitis B surface antigen (+), or hepatitis B cIgG and/or IgM Ab(+) with (-) hepatitis B sAb.
- •d.Diagnosis of active tuberculosis, or latent tuberculosis infection.
- •e.History of cancer.
- •f.History of major surgery within 6 months prior to treatment.
- •g.Lactating women.
- •h.Legal incapacity or limited legal capacity.
研究者
相似试验
招募中
不适用
PHASE 2 STUDY OF AGEN2034 AS MONOTHERAPY OR IN COMBINATION THERAPY WITH AGEN1884 IN SECOND-LINE CERVICAL CANCER-C53 Malignant neoplasm of cervix uteriMalignant neoplasm of cervix uteriC53PER-047-19Agenus Inc.,
招募中
1 期
A phase 2, multicenter, double-blind, two-arm study of subcutaneous RVT-3101 for the treatment of subjects with moderate to severe active crohn’s diseaseCrohn's diseaseCTIS2023-504265-23-00Telavant Inc.113
进行中（未招募）
不适用
A Phase 2 trial for patients with prostate cancer to receive study drugsof CP-751,871 in combination with Docetaxel/Prednisone orDocetaxel/Prednisone alone.Metastatic hormone refractory (androgen indepedent) progressive prostate cancer (HRPC)MedDRA version: 14.0Level: LLTClassification code 10062904Term: Hormone-refractory prostate cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2005-002717-21-DEPfizer Inc. 235 East 42nd Street, New York, NY 10017, USA200
进行中（未招募）
1 期
A PHASE 2, RANDOMIZED, NON-COMPARATIVE, TWO-ARM OPEN LABEL, MULTIPLE-CENTER STUDY OF CP-751,871 IN COMBINATION WITH DOCETAXEL/PREDNISONE IN CHEMOTHERAPY- NAÏVE (ARM A) AND DOCETAXEL/PREDNISONE REFRACTORY (ARM B) PATIENTS WITH HORMONE INSENSITIVE PROSTATE CANCER - n/aMetastatic hormone refractory (androgen indepedent) progressive prostate cancer (HRPC)MedDRA version: 13.1 Level: LLT Classification code 10062904 Term: Hormone-refractory prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2005-002717-21-GBPfizer Inc,235 East 42nd Street, New York,NY 10017200
进行中（未招募）
1 期
A PHASE 2, RANDOMIZED, NON-COMPARATIVE, TWO-ARM OPEN LABEL, MULTIPLE-CENTER STUDY OF CP-751,871 IN COMBINATION WITH DOCETAXEL/PREDNISONE IN CHEMOTHERAPY- NAÏVE (ARM A) AND DOCETAXEL/PREDNISONE REFRACTORY (ARM B) PATIENTS WITH HORMONE INSENSITIVE PROSTATE CANCEREstudio en fase 2, aleatorizado, no comparativo, abierto, multicéntrico, con dos grupos, de CP-751,871 en combinación con docetaxel/prednisona en pacientes con cáncer de próstata resistente a hormonas sin quimioterapia previa (Grupo A) o refractarios a docetaxel /prednisona (Grupo B)Metastatic hormone refractory(androgen independent) progressive prostate cancer (HRPC)Cáncer de próstata progresivo metastásico resistente a hormonas (CPRH) (independiente de andrógenos)EUCTR2005-002717-21-ESPfizer, S.A.120